C-KOPTDialectic Therapeutics
protein degradation, BCL-XL, targeted oncology
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-KOPT
C-KOPTC-KOPTprotein degradation, BCL-XL, targeted oncology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Dialectic Therapeutics protein degradation, BCL-XL, targeted oncology
Dialectic Therapeutics is a biotechnology company developing anti-cancer drugs for patients with few or no other options. Its lead candidate, DT2216, is an Antiapoptotic Protein Targeted Degradation compound that selectively degrades BCL-XL. DT2216 is in Phase 1/2 clinical trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Dialectic Therapeutics — Translational · Lower middle. Derived deterministically from 2 extracted project(s). Most-advanced status: phase 1. Band: translational. Modifiers: +5 modality breadth (2 modalities…
Source: Deterministic